Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe
Author:
Garnier Nicolas, Berghout JoanneORCID, Zygmunt Aldona, Singh Deependra, Huang Kui A., Kantz Waltraud, Blankart Carl RudolfORCID, Gillner Sandra, Zhao Jiawei, Roettger Richard, Saier Christina, Kirschner JanORCID, Schenk Joern, Atkins Leon, Ryan Nuala, Zarakowska Kaja, Zschüntzsch JanaORCID, Zuccolo Michela, Müllenborn MatthiasORCID, Man Yuen-Sum, Goodman Liz, Trad Marie, Chalandon Anne Sophie, Sansen Stefaan, Martinez-Fresno Maria, Badger Shirlene, Walther van Olden Rudolf, Rothmann Robert, Lehner Patrick, Tschohl Christof, Baillon Ludovic, Gumus Gulcin, Gross Edith, Stefanov Rumen, Iskrov Georgi, Raycheva Ralitsa, Kostadinov KostadinORCID, Mitova Elena, Einhorn Moshe, Einhorn Yaron, Schepers Josef, Hübner MiriamORCID, Alves Frauke, Iskandar Rowan, Mayer RudolfORCID, Renieri Alessandra, Piperkova Aneta, Gut Ivo, Beltran Sergi, Matthiesen Mads Emil, Poetz Marion, Hansson Mats, Trollmann Regina, Agolini Emanuele, Ottombrino Silvia, Novelli AntonioORCID, Bertini Enrico, Selvatici Rita, Farnè MariannaORCID, Fortunato Fernanda, Ferlini AlessandraORCID
Abstract
Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic “window of opportunity”. Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository “symptom checkers” for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.
Funder
European Union’s Horizon 2020 research and innovation programme and EFPIA
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference21 articles.
1. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database;S Nguengang Wakap;Eur J Hum Genet,2020 2. The Power of being counted in: Rare-X Website. https://rare-x.org/wp-content/uploads/2022/05/be-counted-052722-WEB.pdf, Accessed 29 December 2022. 3. How many rare diseases are there?;M Haendel;Nat Rev Drug Discov,2020 4. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research;P Kaufmann;Orphanet J Rare Dis,2018 5. EURORDIS Website. www.eurordis.org, Accessed 29 December 2022.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|